Yang · Journal for immunotherapy of cancer 2024 · retrospective cohort study and preclinical animal experiment · n=?

NAD + metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer.

Cited 43 times in the scientific literature.

Level 4 - case-series / case-control

Retrospective human cohort biomarker validation combined with preclinical animal and cell experiments

PubMed 39067875 · doi:10.1136/jitc-2024-009281 · record verified 2026-08-29

What was done

The authors analyzed the association between nicotinamide N-methyltransferase (NNMT) expression in cancer-associated fibroblasts (CAFs) and clinical outcomes in urothelial bladder cancer (UBC) across two patient cohorts using single-cell transcriptomics, immunohistochemistry, and immunofluorescence. Molecular mechanisms and therapeutic targeting were evaluated using chromatin immunoprecipitation, mass spectrometry, CRISPR-Cas9 knockout models, and in vivo UBC mouse models treated with an NNMT inhibitor (5-amino-1-methylquinolinium iodide) and anti-PD-L1 antibody.

What was found

Elevated NNMT expression in CAFs was significantly associated with non-response to PD-L1 blockade and predicted unfavorable prognosis in two UBC cohorts (specific effect sizes, survival times, and p-values not reported in abstract). Mechanistically, NNMT in CAFs drove macrophage recruitment via epigenetic upregulation of serum amyloid A (SAA). In mouse models, NNMT inhibition combined with anti-PD-L1 therapy significantly reduced tumor growth and enhanced apoptosis (quantitative values not reported in abstract).

Why it matters

The study identifies CAF-specific NNMT expression as a driver of immunotherapy resistance through macrophage recruitment in urothelial bladder cancer. Combining NNMT inhibitors with PD-L1 blockade represents a potential strategy to overcome immune checkpoint resistance.

Limits

The abstract does not provide sample sizes, patient characteristics, hazard ratios, or exact statistical metrics. Therapeutic efficacy data rely on preclinical animal models rather than human clinical trials.

Cited by